BCL2L1 and non-small cell lung carcinoma: In addition, quiescent slow-cycling cells display constant expression of Bcl-xl essential for their survival and inhibition of Bcl-xl by ABT-737 resulted in the elimination of quiescent slow-cycling non-small cell lung cancer cells, highlighting the potential therapeutic use of ABT-737 to eradicate slow-cycling cells117.